Moreover, suppression of IL-1 signaling provides cardiovascular benefits in CKD patients who are otherwise at increased risk of cardiovascular events (CVE) due to systemic inflammation and vascular problems associated with CKD progression (94, 95). Here, IL1A is linked to chronic kidney disease.